title: Comparison study of two commercially available methods for the determination of infliximab, adalimumab, etanercept and anti-drug antibody levels.
authors.forename: Begoña
authors.initials: B
authors.lastname: Ruiz-Argüello
authors.forename: Ainhoa Ruiz
authors.initials: AR
authors.lastname: del Agua
authors.forename: Nerea
authors.initials: N
authors.lastname: Torres
authors.forename: Alberto
authors.initials: A
authors.lastname: Monasterio
authors.forename: Antonio
authors.initials: A
authors.lastname: Martínez
authors.forename: Daniel
authors.initials: D
authors.lastname: Nagore
mesh_terms: D000068879:Adalimumab; D000906:Antibodies / Q000097:blood* / Q000276:immunology*; D000911:Antibodies, Monoclonal / Q000097:blood* / Q000276:immunology; D061067:Antibodies, Monoclonal, Humanized / Q000097:blood* / Q000276:immunology; D004797:Enzyme-Linked Immunosorbent Assay; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood* / Q000276:immunology; D000069285:Infliximab; D011933:Reagent Kits, Diagnostic; D018124:Receptors, Tumor Necrosis Factor / Q000097:blood* / Q000276:immunology
chemical_list: D000906:Antibodies; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D011933:Reagent Kits, Diagnostic; D018124:Receptors, Tumor Necrosis Factor; D000069285:Infliximab; D000068879:Adalimumab; D000068800:Etanercept